Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VAS203 · 1 trial · 1 indication
clinical outcome questionnaire
| Arm | Type | Description |
|---|---|---|
| VAS203 (Ronopterin) | EXPERIMENTAL | Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg |
| Saline | PLACEBO_COMPARATOR | Intravenous infusion of physiological saline over 48 hours |
| Name | Type | Description |
|---|---|---|
| VAS203 | DRUG | Treatment |
| Saline | DRUG | Placebo |
Inclusion Criteria: 1. Written informed consent from patient's legal guardian or legal representative or deferred consent procedure, according to local requirements 2. 18 - 60 years of age, inclusive 3. Expected to survive more than 24 hours after admission 4. Traumatic Brain Injury (TBI) within th...
VAS203, also known as Ronopterin, is an investigational small molecule being studied for the treatment of traumatic brain injury. It is intended for patients with moderate and severe traumatic brain injury. The drug is currently in clinical development and has not been approved by regulatory authorities.
VAS203 is being developed by Icon Plc, a company traded on the NASDAQ under the ticker symbol ICLR. The drug is currently in Phase 3 clinical development for traumatic brain injury.
VAS203 is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. A Phase 3 trial has been completed, but the drug remains under investigation.
VAS203 has one completed Phase 3 clinical trial, identified as NCT02794168. This trial, titled 'Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury,' enrolled 224 participants across Austria, France, Germany, Spain, and the United Kingdom.
Yes, VAS203 is also known as Ronopterin. The clinical trial for VAS203, NCT02794168, refers to the drug as Ronopterin in its title. Both names refer to the same investigational small molecule being studied for traumatic brain injury.